Peptide education
Kisspeptin-10
Kisspeptin
Give a healthy man an intravenous dose of kisspeptin-10 and his LH rises within minutes. KP-10 is the ten-amino-acid active fragment of kisspeptin, the signal that sits directly upstream of GnRH neurons, which makes it one of the cleaner research probes in reproductive endocrinology. The same property makes it attractive to clinics selling testosterone support, fertility, and libido. The distance between "moves LH in a monitored IV study" and "fixes your hormones" is the whole story on this page, and the market mostly skips it.
KP-10 reliably moves reproductive hormones in small IV studies, with effects that depend sharply on sex and cycle phase. Nothing published shows it treating low testosterone, infertility, low libido, or the other things clinics advertise.
Overview
Quick answer
The same name shows up in very different settings: small IV physiology studies, ClinicalTrials.gov reproductive-endocrinology registries, clinic and med-spa hormone pages, Reddit or forum talk about PCT and TRT support, vendor listings, and gray-market vials. The route, dose pattern, product controls, and source behind the claim all change how far the evidence can be applied to a clinic vial, forum protocol, or gray-market product.
What is Kisspeptin-10?
The shortest active fragment of the kisspeptin family, also called metastin 45-54 or kisspeptin 112-121, acting on the KISS1R/GPR54 receptor on GnRH neurons. It is an upstream trigger for the reproductive axis: not testosterone, not hCG, and not a growth-hormone peptide.
Why is it discussed?
Because the human physiology is clean: a small IV bolus raises LH and increases LH pulse frequency in healthy men. Clinics, forums, and vendors stretch that into natural testosterone, fertility, libido, delayed puberty, TRT support, and post-cycle recovery, none of which has a controlled KP-10 outcome study behind it.
What routes and amounts appear in studies?
Monitored IV work: boluses from 0.03 to 3 micrograms per kilogram, and a 22.5-hour infusion at 4 micrograms/kg/hour, the setting where testosterone rose in that study. A head-to-head study ran 3-hour infusions of KP-10, KP-54, and GnRH, and GnRH was the most potent. Registry studies include subcutaneous dosing, but nothing here converts into a home protocol.
What shows up outside studies?
Med-spa hormone-optimization menus, Reddit threads about PCT and avoiding hCG, and research-use vials with COAs. Scattered reports mention roughly 100 to 300 micrograms per injection, but there is no converged community protocol, let alone a studied one.
What does a hormone response tell you?
That the axis can move, not that moving it helps. Follicular-phase women did not respond to doses that worked in men and preovulatory women, which shows how context-dependent this axis is. An acute LH bump is a pharmacology result; fertility, libido, and testosterone treatment are outcome claims, and those remain unearned.
Reported practice
Commonly reported protocol
Sparse community reports. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Small human physiology studies reported LH, FSH, gonadotropin-pulse, or GnRH-axis effects after monitored kisspeptin-10 exposure.
ClinicalTrials.gov records place kisspeptin 112-121 in reproductive disorder, delayed-puberty, hypothalamic amenorrhea, and hypogonadotropic hypogonadism research. Registry presence does not mean approved treatment.
Those themes appear in clinic, forum, Reddit, vendor, and gray-market discussion, but the cited KP-10 human studies have not shown lasting benefit for those outcomes.
FDA compounding materials warn that compounded drugs are not FDA-approved before marketing and that some nominated peptide bulk substances raise safety and missing-information concerns. That matters for injectable KP-10 products sold outside controlled studies.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Kisspeptin-10 acutely stimulates LH and the reproductive axis. | This is the best-supported point. Healthy-men physiology work reported rapid LH stimulation and increased LH pulse frequency, and comparative human studies found gonadotropin responses after controlled KP-10 exposure. | KP-10 activates the kisspeptin receptor upstream of GnRH neurons. That explains why LH and FSH are the core readouts in the human studies. | Clinic and forum discussions often use the LH signal as the reason to talk about testosterone or fertility, but those discussions usually skip the tight route, timing, and monitoring used in the studies. | Reasonable for a narrow acute hormone-signaling statement. Too weak for routine hormone-treatment use. |
| Kisspeptin-10 raises testosterone. | The human evidence is context-specific. Acute bolus studies in healthy men mainly support LH and gonadotropin changes, while testosterone increases were described during prolonged infusion and in a small type 2 diabetes/low-testosterone early clinical setting. That is narrow early evidence, not a broad testosterone optimization result. | If KP-10 increases GnRH and LH signaling, testosterone can be downstream in responsive men. That biology is plausible, but it depends on dose pattern, gonadal reserve, baseline endocrine state, and desensitization risk. | Vendor, clinic, Reddit, and forum talk often turns this into "natural testosterone booster" language. The cited KP-10 studies do not give an at-home schedule or a long-term testosterone outcome. | More accurately, this is a hormone-signaling hypothesis with limited human data, not a TRT alternative or testosterone therapy. |
| Kisspeptin-10 helps fertility, puberty, or hypogonadotropic hypogonadism. | ClinicalTrials.gov records and a human probe study place kisspeptin in reproductive-disorder, delayed-puberty, hypothalamic amenorrhea, and hypogonadotropic hypogonadism research. Those are specialist research settings, not general-use treatment instructions. | GnRH, LH, and FSH control reproductive function, so this is a logical research area. The same logic also makes unsupervised use risky because cycle phase, sex, baseline diagnosis, and pulsatile timing can change the response. | Online hormone forums and clinic marketing may talk about fertility, testicular function, and PCT. Those materials cannot show that a gray-market KP-10 vial improves fertility outcomes or safely manages puberty or hypogonadism. | The stronger statement stays with research and diagnostic interest unless stronger outcome trials are added. |
| Kisspeptin-10 improves libido or sexual wellness. | The cited KP-10 sources do not identify a libido or sexual-wellness benefit. Broader kisspeptin-class psychosexual research may exist, but KP-10 vials still need matching isoform, route, and study-population evidence. | Reproductive-axis signaling can influence sex hormones, so the idea is biologically understandable. It still does not measure desire, sexual function, or the relationship between dose timing and symptom change. | Sexual-wellness and libido language is common in clinic and med-spa marketing. Forum reports are mixed and usually lack product verification, dose consistency, and follow-up. | A common market theme, not a supported KP-10 use. |
| A research-use or compounded KP-10 vial is equivalent to study material. | The human studies and registries describe controlled investigational contexts. They leave open the identity, sterility, concentration, and impurity profile of products sold through clinics, vendors, or gray-market channels. | This is a product problem, not a receptor problem. Injectable peptide risk depends on identity, aggregation, peptide-related impurities, endotoxin, sterility, storage, concentration, and dosing accuracy. | Vendors may advertise purity percentages, research-use disclaimers, or COAs. Those documents do not by themselves show FDA-reviewed finished-drug quality or match the material used in human studies. | Product quality needs to be read separately from KP-10 pharmacology. |
Bottom line
Main takeaway
Kisspeptin-10 is an experimental reproductive-axis probe: it moves hormones in small studies, and it is not an approved or proven treatment for testosterone, fertility, libido, puberty, or anti-aging.
The evidence ladder runs IV physiology studies, then registry-stage reproductive-disorder research, then clinic marketing, then forum anecdotes, in that order of reliability. Note the route gap: almost everything solid is IV, and almost everything sold is meant for subcutaneous or intramuscular use.
The anchors: the healthy-men LH pulse study, the menstrual-phase dimorphism study, the KP-10 versus KP-54 versus GnRH infusion comparison, the IHH probe study, and the ClinicalTrials.gov footprint. Together they define a research instrument, not a therapy.
Identity
What it is
Kisspeptin-10 is the active C-terminal decapeptide of the KISS1 gene product, signaling through KISS1R on GnRH neurons at the top of the reproductive axis. Its human half-life is about 3.8 minutes intravenously, which is why studies use boluses and infusions rather than daily shots.
As a probe, it is excellent. Small controlled doses produce fast, measurable LH and FSH changes, so researchers use it to map reproductive physiology in healthy volunteers, to test GnRH neuronal function in idiopathic hypogonadotropic hypogonadism, and in registry-stage work on delayed puberty and hypothalamic amenorrhea.
As a product, it is unresolved. Responses depend on sex, menstrual phase, baseline endocrine state, and exposure pattern; FDA's review flags tachyphylaxis and desensitization with continuous high-dose exposure; and the jump from IV hormone spikes to subcutaneous clinic vials is a jump in route, schedule, formulation, and product quality all at once.
How people talk about it online
Clinic and med-spa pages sell KP-10 as hormone optimization: natural testosterone, fertility, libido, sexual wellness, and the appeal of avoiding direct hormone replacement. The marketing treats an acute signaling effect as if it were a treatment outcome.
Reddit and forum threads are more openly experimental: PCT after anabolic use, TRT support, hCG comparisons, and curiosity about whether a short peptide can restart an axis. Reported amounts scatter around 100 to 300 micrograms with no convergence and no verification.
Vendor listings emphasize research-use labels, purity percentages, and COAs. Those are market cues, and they say nothing about whether a vial matches study material or meets sterile injectable quality.
Use context
Routes, doses, and cycle patterns
The study literature is mostly controlled IV bolus or infusion work, with registry-stage reproductive-endocrinology studies that may include subcutaneous exposure. The online market discusses SC or IM products and hormone-cycle goals, but the cited KP-10 sources do not establish a dependable repeatable dose, frequency, or cycle length for clinic, forum, or gray-market use.
Human studies and product labels
Healthy-men IV bolus and infusion study
- Purpose
- Acute LH, FSH, and testosterone physiology
- Context
- PubMed human physiology study
- Route
- IV
- Amount
- 0.03 to 3 micrograms/kg IV bolus; separate 3 micrograms/kg bolus followed by 4 micrograms/kg/hour infusion
- Frequency
- Single monitored exposure in the study setting
- Duration
- Bolus testing and a 22.5-hour infusion arm
Lower IV bolus doses increased LH in healthy men, while the prolonged infusion setting is where testosterone increases were reported. This does not translate into a home injection schedule.
Menstrual-phase response study
- Purpose
- Sex- and cycle-phase endocrine response
- Context
- PubMed human physiology study
- Route
- IV and subcutaneous exposure in the study
- Amount
- Men responded at low nmol/kg IV bolus doses; follicular-phase women were tested up to 10 nmol/kg IV bolus, 32 nmol/kg SC bolus, and 720 pmol/kg/min IV infusion; preovulatory women received 10 nmol/kg IV bolus
- Frequency
- Single monitored study exposures
- Duration
- Acute endocrine-response testing
Men and preovulatory women showed gonadotropin responses, while follicular-phase women did not respond in the same way. That cycle-phase dependence is a major reason simple fertility or libido claims are too broad.
KP-10 versus KP-54 versus GnRH comparison
- Purpose
- Direct comparison of gonadotropin output
- Context
- PubMed human physiology study
- Route
- IV
- Amount
- KP-10, KP-54, and GnRH at 0.1, 0.3, and 1.0 nmol/kg/hour
- Frequency
- Separate study days
- Duration
- 3-hour infusions
KP-10 and KP-54 produced similar gonadotropin output at tested IV doses, while GnRH was more potent. The comparison also helps explain why KP-54 and other kisspeptin forms are not automatic substitutes for KP-10.
Hypogonadotropic hypogonadism probe and registry studies
- Purpose
- GnRH-neuronal function and reproductive-disorder research
- Context
- PubMed probe study and ClinicalTrials.gov registries
- Route
- Exogenous kisspeptin in controlled research; registry route varies by study
- Amount
- Not consistently specified
- Frequency
- Registry schedules vary and are not general-use treatment instructions
- Duration
- Registry studies include acute, prolonged pulsatile, and multi-week research designs
These sources explain why specialists study GnRH deficiency and reproductive-disorder settings. They are not directions for personal use.
Real-world discussion
Sparse community reports
- Purpose
- Reproductive-axis and fertility discussion
- Context
- Forums and niche vendors
- Route
- Subcutaneous injection in scattered reports
- Amount
- No consistent community range exists; scattered reports describe roughly 100 to 300 mcg per administration
- Frequency
- Inconsistent across reports
- Duration
- Inconsistent across reports
Kisspeptin is a serious reproductive-axis research tool used in clinical studies of fertility triggering, but it has no developed self-use culture. The figures above are scattered reports, not a converged pattern. Reported as context, not a recommendation.
What varies
- Goal: acute LH signaling, fertility, puberty evaluation, libido, PCT, and testosterone support are different claims.
- Route: the most detailed human KP-10 dose details are monitored IV bolus or infusion designs, while online use often talks about injectable vials without the same evidence.
- Timing: pulsatile signaling and cycle phase matter for reproductive endocrinology; an unstructured intermittent schedule may not reproduce study physiology.
- Product: study material, compounded supply, clinic inventory, and gray-market vials can differ in identity, sterility, concentration, impurities, and storage.
Human data
Human evidence
Real but narrow, and mostly about hormone movement rather than outcomes. Small controlled studies show rapid LH and FSH responses after IV KP-10, a testosterone rise during a 22.5-hour infusion, strong dependence on sex and menstrual phase, and GnRH outperforming KP-10 head to head. Registry records extend the work into hypogonadotropic hypogonadism, delayed puberty, and hypothalamic amenorrhea. No study shows lasting benefit for testosterone replacement, fertility, libido, anti-aging, PCT, or TRT support, and no FDA-approved KP-10 product exists.
Evidence maturity
KP-10 reliably moves reproductive hormones in small human studies but remains an investigational research peptide with no approved product or outcome-trial base.
Small controlled IV studies showed acute LH and FSH responses with strong sex and menstrual-cycle-phase dependence.
Exogenous kisspeptin was used to probe GnRH neuronal function in idiopathic hypogonadotropic hypogonadism, not as a treatment.
ClinicalTrials.gov records cover reproductive disorders, delayed puberty, and hypothalamic amenorrhea without translating into an approved therapy.
No FDA-approved KP-10 product; clinic, vendor, and gray-market vials circulate with scattered, non-standardized use reports.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Healthy-men LH pulse physiology | Healthy adult men | Small human physiology study | Investigational peptide in a controlled research setting | KP-10 rapidly stimulated LH and increased LH pulse frequency in the study setting. | Small sample, acute endocrine endpoints, monitored IV exposure, and no lasting treatment or general-use product outcome. | moderate |
| Male/female and menstrual-phase response | Healthy men and healthy women studied in menstrual-cycle contexts | Small comparative human physiology study | Investigational peptide in a controlled research setting | Men and preovulatory women showed gonadotropin responses; follicular-phase women lacked the same response pattern in the study. | Very small groups and strong cycle-phase dependence make broad fertility or libido claims unreliable. | moderate |
| Exogenous kisspeptin in idiopathic hypogonadotropic hypogonadism | Patients with congenital idiopathic hypogonadotropic hypogonadism | Human mechanistic probe study | Specialist reproductive-endocrinology research | Exogenous kisspeptin was used as a probe of GnRH neuronal function rather than as an established treatment. | A probe study is useful for endocrine physiology. It is not an approved therapy, fertility-outcome study, or public dosing schedule. | weak |
| KP-10, KP-54, and GnRH direct comparison | Healthy men | Small controlled human physiology comparison | Investigational peptide and GnRH comparison | KP-10 and KP-54 produced similar gonadotropin secretion at tested doses, while GnRH was more potent. | Comparative hormone output answers an acute physiology question, not disease treatment, fertility benefit, libido improvement, or gray-market product performance. | moderate |
| ClinicalTrials.gov reproductive-disorder registry footprint | Adults with reproductive disorders, adolescents evaluated for delayed puberty, and women with hypothalamic amenorrhea or hypogonadotropic hypogonadism | Completed registry records | Investigational reproductive-endocrinology research | Registries show adult, delayed-puberty, hypothalamic amenorrhea, and hypogonadotropic hypogonadism research activity. | Registry entries show that research was planned or run; they do not by themselves show approval, positive results, or public-use instructions. | weak |
Cautions
Safety and unknowns
- Repeated-use safety is much less clear than acute monitored-study exposure, especially for SC or IM products sold outside a trial.
- Reproductive-axis effects can be context-dependent by sex, menstrual phase, baseline endocrine diagnosis, gonadal reserve, and timing of exposure.
- FDA's review flags tachyphylaxis and desensitization concerns with continuous high-dose exposure; that is especially relevant when people assume more frequent stimulation means better results.
- FDA compounding materials make product quality part of the safety question: compounded drugs are not FDA-approved before marketing, and some peptide bulk substances have missing safety information and impurity concerns.
- Gray-market and research-use products may lack reliable adverse-event reporting, lot-level sterility evidence, endotoxin controls, concentration confirmation, and storage documentation.
Product quality
A vial label is only a starting point
Study evidence does not verify every vial labeled KP-10. Human physiology studies used controlled material and monitoring; vendor or clinic products need their own identity and quality evidence.
A COA can be a narrow analytical document. Sterile injectable quality, correct concentration after reconstitution, endotoxin control, representative sampling, shipping stability, and proper storage still require finished-product evidence.
Identity
KP-10, broader kisspeptin forms, and agonist analogues can differ in kinetics, route, and evidence; use only data tied to the exact compound.
Sterility and endotoxin
Injectable use makes microbial contamination and endotoxin control just as important as a purity percentage.
Peptide-related impurities
Degradation products, aggregation, and synthesis impurities can change safety risk even when a seller advertises high purity.
Concentration and dose math
Online vial strengths, reconstitution volumes, and syringe-unit math can create large dosing errors if the product and concentration are not independently verified.
Storage and shipping
Peptides can degrade with poor temperature control, light exposure, repeated freeze-thaw handling, or unclear post-reconstitution storage.
Mechanism
How it is proposed to work
Kisspeptin-10 activates the kisspeptin receptor upstream of GnRH neurons. GnRH then drives pituitary LH and FSH signaling, which can affect downstream reproductive hormones such as testosterone in responsive settings.
The short KP-10 fragment keeps the biologically active C-terminal region of kisspeptin, which is why small doses can produce measurable gonadotropin changes in controlled studies.
The response is not uniform. Sex, menstrual-cycle phase, baseline endocrine state, route, dose, infusion pattern, and receptor desensitization can all change what happens after exposure.
KP-10 is not hCG, testosterone, or GnRH. It is an upstream signal, so its effects depend on whether the rest of the hypothalamic-pituitary-gonadal axis can respond.
It signals through KISS1R (GPR54) on GnRH neurons and sits at the top of the reproductive axis, which is why it is used as a precise research probe for triggering downstream LH and FSH release.
FAQ
Common questions
Is kisspeptin-10 an approved fertility, libido, or testosterone treatment?
No approved product was verified. The human material found here is limited to small physiology studies and completed ClinicalTrials.gov research records in reproductive-endocrinology contexts.
What can the human studies actually support?
They support a narrow mechanistic claim: kisspeptin-10 can influence GnRH and gonadotrophin-axis signaling in controlled human studies. They are too narrow for public fertility plans, puberty management, testosterone therapy, or libido enhancement.
Why is it research-only?
Because the evidence is investigational and study-specific. Translating registry interventions or physiology-study methods into public recommendations would overstate what those studies show.
Details
Technical details
Sources
References
- 1.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.
- 2.
FDA. Compounding and the FDA: Questions and Answers 2026.
Accessed 2026-06-08.
FDA explains that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before marketing.
- 3.
ClinicalTrials.gov. Kisspeptin Administration in the Adult 2026.
NCT00914823 Accessed 2026-06-09.
Completed phase 1 Massachusetts General Hospital registry record covering adult reproductive-disorder research contexts including hypogonadotropic hypogonadism, Kallmann syndrome, GnRH deficiency, PCOS, and hyperprolactinemia.
- 4.
ClinicalTrials.gov. Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism 2026.
NCT04648969 Accessed 2026-06-09.
Completed phase 2 registry record in hypogonadotropic hypogonadism describing investigational development through exogenous kisspeptin rather than an approved therapy lane.
- 5.
ClinicalTrials.gov. Kisspeptin in the Evaluation of Delayed Puberty 2026.
NCT01438034 Accessed 2026-06-09.
Completed phase 1 registry record studying whether kisspeptin could help distinguish self-resolving from permanent delayed puberty in adolescents.
- 6.
ClinicalTrials.gov. Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders 2026.
NCT05633966 Accessed 2026-06-09.
Completed phase 1 registry record in women with hypothalamic amenorrhea or hypogonadotropic hypogonadism assessing reproductive-hormone response in a research setting.
- 7.
PubMed. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. 2011.
doi:10.1210/jc.2011-1408 PMID:21976724 Accessed 2026-06-09.
Small human physiology study reporting gonadotropin responses in healthy men and preovulatory women, with no response in women studied during the follicular phase.
- 8.
PubMed. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. 2011.
doi:10.1210/jc.2011-0089 PMID:21632807 Accessed 2026-06-09.
Healthy-men physiology study identifying kisspeptin-10 as the minimal bioactive kisspeptin sequence and reporting rapid LH stimulation with increased pulse frequency in the study setting.
- 9.
doi:10.1210/jc.2014-2233 PMID:25226293 Accessed 2026-06-09.
Human study using exogenous kisspeptin as a probe of GnRH-neuronal function in congenital idiopathic hypogonadotropic hypogonadism rather than as established treatment evidence.
- 10.
doi:10.1093/humrep/dev143 PMID:26089302 Accessed 2026-06-09.
Small healthy-men physiology study reporting that kisspeptin-10 and kisspeptin-54 produced similar gonadotrophin secretion, while GnRH was more potent in that controlled comparison.